Purpose: Although all studies confirm that BRCA1 tumors are highly prolifer
ative and poorly differentiated, their outcomes remain controversial. We pr
opose to examine, through a cohort study, the pathologic characteristics, o
verall survival, local recurrence, and metastasis-free intervals of 40 pati
ents with BRCA1 breast cancer.
Patients and Methods: A cohort of 183 patients with invasive breast cancer,
treated at the Institut Curie and presenting with a familial history of br
east and/or ovarian cancer, were tested for BRCA1 germ-line mutation. Tumor
characteristics and clinical events were extracted from our prospectively
registered database.
Results: Forty BRCA1 mutations were found among the 183 patients (22%). Med
ian follow-up was 58 months. BRCA1 tumors were larger in size (P =.03), had
a higher rate of grade 3 histoprognostic factors (P =,002), and had a high
er frequency of negative estrogen (P =.003) and progesterone receptors (P =
.002) compared with non-BRCA1 tumors. Overall survival was poorer for carri
ers than for noncarriers (5-year rate, 80% v 91%, P =.002), Because a long
time interval between cancer diagnosis and genetic counseling artificially
increases survival time due to unrecorded deaths, the analysis was limited
to the 110 patients whose diagnosis-to-counseling interval war less than 36
months (19 BRCA1 patients and 91 non-BRCA1 patients), The differences betw
een the BRCA1 and non-BRCA1 groups regarding overall survival and metastasi
s-free interval were dramatically increased (49% v 85% and 18% v 84%, respe
ctively). Multivariate analysis showed that BRCA1 mutation was an independe
nt prognostic factor.
Conclusion: Our results strongly support that among patients with familial
breast cancer, those who have a BRCA1 mutation have a worse outcome than th
ose who do not. J Clin Oncol 18:4053-4059. (C) 2000 by American Society of
Clinical Oncology.